Study/year | Number of patients | Main conclusion |
---|---|---|
TOTAL 20157 | 10 732 | No difference in cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA class IV heart failure within 180 days but increased risk of stroke at 30 days |
TASTE 201414 | 7244 | No difference in death, or death, rehospitalisation for MI or ST after 12 months |
TROFI 201315 | 141 | Similar flow and stent area, as assessed by OCT |
EXPORT 200816 | 249 | No differences at 30 days in the rate of major adverse cardiac and cerebral events |
NONSTOP 200417 | 258 | No difference in no-reflow or slow flow phenomena |
PIHRATE 201018 | 196 | No difference in ST resolution 60 min after PPCI, no difference in mortality at 6 months |
ITTI 201219 | 100 | No difference in 6-month MACE rate (death, reinfarction, target lesion revascularisation and stroke) |
MUSTELA 201220 | 208 | In patients with high thrombus load, TA yielded better postprocedural STR and reduced MVO at 3 months, but was not associated with a reduction in infarct size and transmurality |
INFUSE-AMI 20128 | 452 | In patients with large anterior STEMI undergoing PPCI with bivalirudin, infarct size at 30 days was significantly reduced by bolus intracoronary abciximab delivered to the infarct lesion site but not by manual aspiration thrombectomy |
VAMPIRE 20082 | 355 | Reduced MACE rate after 8 months in the TA group |
TAPAS 20083 | 1,071 | Improved ST-segment resolution and clinical outcome |
MACE, major adverse cardiac event; MI, myocardial infarction; MOV, microvascular obstruction; NYHA, New York Heart Association; OCT, optical coherence tomography; PPCI, primary percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; STR, ST-segment resolution; TA, thrombus aspiration.